Cargando…

Detection of tumor‐derived cell‐free DNA from colorectal cancer peritoneal metastases in plasma and peritoneal fluid

Tumor‐derived cell‐free DNA (cfDNA) is an emerging biomarker for guiding the personalized treatment of patients with metastatic colorectal cancer (CRC). While patients with CRC liver metastases (CRC‐LM) have relatively high levels of plasma cfDNA, little is known about patients with CRC peritoneal m...

Descripción completa

Detalles Bibliográficos
Autores principales:	van't Erve, Iris, Rovers, Koen P, Constantinides, Alexander, Bolhuis, Karen, Wassenaar, Emma CE, Lurvink, Robin J, Huysentruyt, Clément J, Snaebjornsson, Petur, Boerma, Djamila, van den Broek, Daan, Buffart, Tineke E, Lahaye, Max J, Aalbers, Arend GJ, Kok, Niels FM, Meijer, Gerrit A, Punt, Cornelis JA, Kranenburg, Onno, de Hingh, Ignace HJT, Fijneman, Remond JA
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley & Sons, Inc. 2021
Materias:	Brief Report
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8073000/ https://www.ncbi.nlm.nih.gov/pubmed/33635598 http://dx.doi.org/10.1002/cjp2.207

Ejemplares similares

Repetitive electrostatic pressurised intraperitoneal aerosol chemotherapy (ePIPAC) with oxaliplatin as a palliative monotherapy for isolated unresectable colorectal peritoneal metastases: protocol of a Dutch, multicentre, open-label, single-arm, phase II study (CRC-PIPAC)
por: Rovers, Koen P, et al.
Publicado: (2019)

First-line palliative systemic therapy alternated with electrostatic pressurised intraperitoneal aerosol chemotherapy (oxaliplatin) for isolated unresectable colorectal peritoneal metastases: protocol of a multicentre, single-arm, phase II study (CRC-PIPAC-II)
por: Lurvink, Robin J., et al.
Publicado: (2021)

Patient-reported outcomes during repetitive oxaliplatin-based pressurized intraperitoneal aerosol chemotherapy for isolated unresectable colorectal peritoneal metastases in a multicenter, single-arm, phase 2 trial (CRC-PIPAC)
por: Lurvink, Robin J., et al.
Publicado: (2021)

Peritoneal Metastases From Colorectal Cancer: Defining and Addressing the Challenges
por: Kranenburg, Onno, et al.
Publicado: (2021)

Peritoneal metastases from colorectal cancer belong to Consensus Molecular Subtype 4 and are sensitised to oxaliplatin by inhibiting reducing capacity
por: Laoukili, Jamila, et al.
Publicado: (2022)

Adjuvant hyperthermic intraperitoneal chemotherapy (HIPEC) in patients with colon cancer at high risk of peritoneal carcinomatosis; the COLOPEC randomized multicentre trial
por: Klaver, Charlotte E L, et al.
Publicado: (2015)

Patient selection for cytoreductive surgery and HIPEC for the treatment of peritoneal metastases from colorectal cancer
por: Simkens, Geert A, et al.
Publicado: (2017)

Organoids from colorectal peritoneal metastases as a platform for improving hyperthermic intraperitoneal chemotherapy
por: Ubink, I., et al.
Publicado: (2019)

The impact of body weight on the development of peritoneal metastases in colorectal cancer patients: results from a nationwide cohort study
por: van de Vlasakker, Vincent C. J., et al.
Publicado: (2023)

Incidence and predictors of peritoneal metastases of gynecological origin: a population-based study in the Netherlands
por: Burg, Lara, et al.
Publicado: (2020)

Effective Strategies to Predict Survival of Colorectal Peritoneal Metastases Patients Eligible for Cytoreductive Surgery and HIPEC
por: Simkens, Geert A, et al.
Publicado: (2021)

Second and third look laparoscopy in pT4 colon cancer patients for early detection of peritoneal metastases; the COLOPEC 2 randomized multicentre trial
por: Bastiaenen, Vivian P., et al.
Publicado: (2019)

The Burden of Peritoneal Metastases from Gastric Cancer: A Systematic Review on the Incidence, Risk Factors and Survival
por: Rijken, Anouk, et al.
Publicado: (2021)

Comparing patient reported abdominal pain between patients treated with oxaliplatin-based pressurized intraperitoneal aerosol chemotherapy (PIPAC-OX) and primary colorectal cancer surgery
por: van de Vlasakker, Vincent C. J., et al.
Publicado: (2023)

Major influence of postoperative complications on costs of cytoreductive surgery and HIPEC in patients with colorectal peritoneal metastases
por: Simkens, Geert A., et al.
Publicado: (2018)

2022 Peritoneal Surface Oncology Group International Consensus on HIPEC Regimens for Peritoneal Malignancies: Colorectal Cancer
por: Hübner, Martin, et al.
Publicado: (2023)

Postoperative circulating tumour DNA is associated with pathologic response and recurrence-free survival after resection of colorectal cancer liver metastases
por: Bolhuis, Karen, et al.
Publicado: (2021)

Paving the Road Towards Non-Invasive Molecular Imaging
por: Fijneman, Remond J.A.
Publicado: (2006)

Comparison of the Peritoneal Cancer Index and Dutch region count as tools to stage patients with peritoneal metastases of colorectal cancer
por: Verheij, F. S., et al.
Publicado: (2020)

Synchronous peritoneal metastases from lung cancer: incidence, associated factors, treatment and survival: a Dutch population-based study
por: Lurvink, Robin J., et al.
Publicado: (2021)

Metachronous Peritoneal Metastases After Adjuvant Chemotherapy are Associated with Poor Outcome After Cytoreduction and HIPEC
por: Sluiter, Nina R., et al.
Publicado: (2018)

Perioperative systemic therapy and cytoreductive surgery with HIPEC versus upfront cytoreductive surgery with HIPEC alone for isolated resectable colorectal peritoneal metastases: protocol of a multicentre, open-label, parralel-group, phase II-III, randomised, superiority study (CAIRO6)
por: Rovers, Koen P., et al.
Publicado: (2019)

The impact of an open or laparoscopic approach on the development of metachronous peritoneal metastases after primary resection of colorectal cancer: results from a population-based cohort study
por: Lurvink, Robin J., et al.
Publicado: (2022)

Treatment Strategies and Prognosis of Patients With Synchronous or Metachronous Colorectal Peritoneal Metastases: A Population-Based Study
por: Bakkers, C., et al.
Publicado: (2021)

Outcomes of Combined Peritoneal and Local Treatment for Patients with Peritoneal and Limited Liver Metastases of Colorectal Origin: A Systematic Review and Meta-Analysis
por: Polderdijk, Margot C. E., et al.
Publicado: (2021)

Concomitant intraperitoneal and systemic chemotherapy for extensive peritoneal metastases of colorectal origin: protocol of the multicentre, open-label, phase I, dose-escalation INTERACT trial
por: de Boer, Nadine Leonie, et al.
Publicado: (2019)

Treating colorectal peritoneal metastases with an injectable cytostatic loaded supramolecular hydrogel in a rodent animal model
por: Wintjens, Anne G. W. E., et al.
Publicado: (2023)

Updated Incidence, Treatment and Survival of a Nationwide Cohort of Patients with Peritoneal Metastases of Unknown Origin
por: Rijken, Anouk, et al.
Publicado: (2022)

Metastatic Colorectal Cancer Treatment Response Evaluation by Ultra-Deep Sequencing of Cell-Free DNA and Matched White Blood Cells
por: van 't Erve, Iris, et al.
Publicado: (2023)

Primary tumor resection or systemic treatment as palliative treatment for patients with isolated synchronous colorectal cancer peritoneal metastases in a nationwide cohort study
por: Rijken, Anouk, et al.
Publicado: (2023)

Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy versus palliative systemic chemotherapy in stomach cancer patients with peritoneal dissemination, the study protocol of a multicentre randomised controlled trial (PERISCOPE II)
por: Koemans, W. J., et al.
Publicado: (2019)

Treatment of Peritoneal Dissemination in Stomach Cancer Patients With Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy (HIPEC): Rationale and Design of the PERISCOPE Study
por: van der Kaaij, Rosa T, et al.
Publicado: (2017)

A population‐based study on the prognostic impact of primary tumor sidedness in patients with peritoneal metastases from colon cancer
por: de Boer, Nadine L., et al.
Publicado: (2020)

Peritoneal Metastases from Extraperitoneal Primary Tumors: Incidence, Treatment, and Survival from a Nationwide Database
por: Rijken, Anouk, et al.
Publicado: (2022)

Synchronous and Metachronous Peritoneal Metastases in Patients with Left-Sided Obstructive Colon Cancer
por: Veld, Joyce Valerie, et al.
Publicado: (2020)

Dedicated MRI staging versus surgical staging of peritoneal metastases in colorectal cancer patients considered for CRS-HIPEC; the DISCO randomized multicenter trial
por: Engbersen, M. P., et al.
Publicado: (2021)

DNA and RNA Alterations Associated with Colorectal Peritoneal Metastases: A Systematic Review
por: Heuvelings, Danique J. I., et al.
Publicado: (2023)

Intraperitoneal Chemotherapy for Unresectable Peritoneal Surface Malignancies
por: Guchelaar, Niels A. D., et al.
Publicado: (2023)

Perioperative Systemic Therapy Versus Cytoreductive Surgery and HIPEC Alone for Resectable Colorectal Peritoneal Metastases: Patient-Reported Outcomes of a Randomized Phase II Trial
por: Bakkers, C., et al.
Publicado: (2023)

Genetic Variants in DNA Repair Pathways as Potential Biomarkers in Predicting Treatment Outcome of Intraperitoneal Chemotherapy in Patients With Colorectal Peritoneal Metastasis: A Systematic Review
por: Hulshof, Emma C., et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_ru67kcnk8rcgrdp2ge3ih5m2dk